Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001714899-24-000219
Filing Date
2024-11-13
Accepted
2024-11-13 16:18:59
Documents
1
Period of Report
2024-11-11

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1731532732.html 4  
1 FORM 4 wk-form4_1731532732.xml 4 11004
  Complete submission text file 0001714899-24-000219.txt   12479
Mailing Address C/O BLUEBIRD BIO, INC. 840 MEMORIAL DRIVE CAMBRIDGE MA 02139
Business Address
Schenkein David P (Reporting) CIK: 0001578200 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38311 | Film No.: 241454569

Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Issuer) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)